The groundbreaking success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a challenging picture. While early returns were significant, the cessation of website patents and the rise of less expensive alternatives have diminished the customer base. Conse